文献速递肝病

非肝硬化性非酒精性脂肪性肝炎治疗试验终点的批判性综述

A critical review of endpoints for non-cirrhotic NASH therapeutic trials.
PubMed 文献 · J Hepatol · 2017-12-06

非酒精性脂肪性肝炎缺乏单一特异性诊断标志物,需多指标衡量疗效,且候选药物靶点机制多样,故药物研发需序贯采用多类终点。组织学终点仍被视为临床结局的最佳预测指标,但仅在较大规模晚期试验中可可靠检验。本文综述不同试验阶段特定终点的依据与临床数据,并讨论当前IIb期组织学终点(尤其纤维化降低一个分期)预测进展为肝硬化的效力与局限。

要点

  • 非酒精性脂肪性肝炎无单一特异性诊断标志物,需多指标衡量疗效。
  • 组织学终点仍被视为临床结局的最佳预测指标,但仅在较大规模晚期试验中可可靠检验。
  • 本文讨论IIb期组织学终点(尤其纤维化降低一个分期)预测肝硬化的效力与局限。

核心结论

  • 组织学终点仍被视为临床结局的最佳预测指标,但仅在较大规模晚期试验中可可靠检验。
  • 当前IIb期组织学终点(尤其纤维化降低一个分期)预测进展为肝硬化的效力与局限仍需讨论。

研究设计与样本

  • 本文为针对非肝硬化性非酒精性脂肪性肝炎治疗试验终点的批判性综述,检索范围原文未报告。

主要发现

  • 非酒精性脂肪性肝炎缺乏单一特异性诊断标志物,需多指标衡量疗效。
  • 候选药物靶向多种被认为促进肝损伤的机制,故需序贯达到广泛终点。
  • 部分终点验证作用机制,另一些用于预判组织学疗效。
  • 组织学终点仍被视为临床结局的最佳预测指标,但仅在较大规模晚期试验中可可靠检验。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-alcoholic steatohepatitis is a disease without a single, specific, diagnostic marker, hence multiple indicators are required to measure therapeutic efficacy. Moreover, drug candidates for non-alcoholic steatohepatitis target many distinct mechanisms that are believed to promote hepatic injury. Therefore, a wide range of endpoints must be reached, sequentially, as required by the drug development process. Some of these endpoints validate the mechanism of action, others are used to anticipate histological efficacy. Histological endpoints are still considered the best predictors of clinical outcome, but they can only be reliably tested in larger, late phase trials. Herein, we will review the rationale and clinical data supporting the use of specific endpoints at different stages of therapeutic trials. We will also discuss the validity and limitations of current phase IIb histological endpoints, particularly a one stage reduction in fibrosis, for their ability to predict progression to cirrhosis, which is the ultimate outcome measure in therapeutic trials.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Ratziu V. A critical review of endpoints for non-cirrhotic NASH therapeutic trials. J Hepatol. 2017. PMID: 29223369. doi:10.1016/j.jhep.2017.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。